Duration of Sodium Zirconium Cyclosilicate Treatment and Continuation of RAASi Therapy After a Hyperkalaemia Episode
Patients with longer SZC treatment experience sustained protection against RAASi discontinuation, and the risk of RAASi discontinuation resumes once SZC is discontinued.
Authors
- Ignacio Sánchez‐Lázaro (ORCID: https://orcid.org/0000-0003-2851-4153)
- Eiichiro Kanda (ORCID: https://orcid.org/0000-0003-0676-096X)
- Stefan Franzén (ORCID: https://orcid.org/0000-0002-9640-0927)
- Anna Lipińska (ORCID: https://orcid.org/0000-0002-5116-0210)
- Toyoaki Murohara (ORCID: https://orcid.org/0000-0003-2723-6243)
- Charles V. Pollack (ORCID: https://orcid.org/0000-0002-1214-7881)
- Eva Lesén (ORCID: https://orcid.org/0000-0002-2198-4382)
- Anjay Rastogi (ORCID: https://orcid.org/0000-0002-8117-6010)
- David Arroyo (ORCID: https://orcid.org/0000-0003-4652-0311)
- Christen M. Gray (ORCID: https://orcid.org/0000-0002-9723-3032)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of London (GB)
- University of California, Los Angeles (US)
- Kawasaki Medical School (JP)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- University of Mississippi (US)
- London School of Hygiene & Tropical Medicine (GB)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Sweden) (SE)
- Nagoya University (JP)
- University of Gothenburg (SE)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-12-10
- DOI
- https://doi.org/10.1002/ehf2.15171
- Citations
- 3
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- AstraZeneca